RxDoctor Payments Data

Kevin Lenhart, MD

Cardiovascular Disease · Branford, CTNPI 1417956012

Payments from drug & device makers

$2,870in general payments, 2019–2025

Across 125 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$477
  • Pfizer$403
  • Amgen$380
  • Boston Scientific$356
  • Merck$306
  • Boehringer Ingelheim$193
  • plus $755 from 9 others

What the payments were for

  • Food & beverage$2,870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,870 in reported general payments places this provider in the 60th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$77,255
Medicare patients
481
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban319$328,868
XareltoRivaroxaban44$73,416
EntrestoSacubitril/Valsartan67$68,643
JardianceEmpagliflozin44$53,817
Praluent PenAlirocumab12$6,244
Metoprolol Succinate255$3,054
Valsartan108$2,679
Atorvastatin Calcium172$1,739
Amlodipine Besylate224$1,592
Labetalol Hcl49$1,410
Amiodarone Hcl20$1,371
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,351
Carvedilol114$1,204
Metoprolol Tartrate141$1,198
Nebivolol Hcl31$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$403$328,868319 claims
Johnson & JohnsonXarelto$88$73,41644 claims
NovartisEntresto$191$68,64367 claims
Boehringer IngelheimJardiance$193$53,81744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Branford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →